Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. 

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France

     GENTAUR France SARL
    9, rue Lagrange, 75005 Paris 
    Tel 01 43 25 01 50 
    Fax 01 43 25 01 60
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Germany

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA

    usa-flagGenprice Inc, Logistics
    547, Yurok Circle
    San Jose, CA 95123
    Phone/Fax: 

    (408) 780-0908 

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    skype chat

    GENPRICE Inc. invoicing/ accounting:
    6017 Snell Ave, Suite 357
    San Jose, CA. 96123

     

    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     

    Displaying items by tag: Gentaur
    Monday, 11 March 2013 15:15

    Knock-in and Knock-out Rat

    Targatt provides a complete range of gene targeting services in rats to generate transgenic knock-in and knock-out rat models.

    Rats are more versatile research model animals than mice since they are physiologically more similar to humans. The recent isolation of rat embryonic stem (ES) cells opened the doors to the generation of transgenic rats and we are proud to be one of the first providers of an all-inclusive transgenic rat generation service. Our competence in gene-targeting vector design coupled with our expertise in culturing rat ES cells allows us to offer a high-quality customized service for the generation of transgenic knock-in and knock-out rats.

    Using our proprietary germline competent rat ES cell lines we can create your customized transgenic rat model, including

    • - Constitutive knockin/out
    • - Conditional knockin/out
    • - Inducible knockin/out
    • - Point mutations
    • - Random integration
    • - Insertion of reporter genes
    • - Humanized rat models
    • - Disease rat models
    • knock-in-knock-out-mouse-targatt-1

     

    We take great pride in offering you the highest level of service and we are committed to ensuring the success of your transgenic rat project. Our service includes an initial project assessment based on your model requirements. A dedicated PhD level project manager will discuss available gene targeting vector design strategies and will update you continuously throughout the project.

    We provide the most flexible customized service options whether you’d like us to do all the work or are on a tight budget and prefer doing some steps yourself.

     Full Transgenic Rat Generation Service Includes:

    • - Gene targeting vector design, construction and sequencing
    • - Rat ES cell targeting, screening and expansion of positive rat ES cell clones
    • - Karyotyping of targeted rat ES cells
    • - Chimera production via blastcyst injection
    • - Chimera breeding for germline transmission
    • - Genotyping of offspring
    • - Transfer of heterozygous targeted rats to the customer
    • - Optional: breeding to generate homozygous rats

     

    All our animals are housed in a facility that is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International, has an Assurance on file with the Office of Laboratory Animal Welfare (OLAW), and is a registered research facility with the U.S. Department of Agriculture.

    knock-in-knock-out-mouse-targatt-2

    We also offer Knock-in/Knock-out Mouse and Transgenic Mouse (Random Insertion) services. For more information please contact us.

     

    Published in Targatt services
    Monday, 11 March 2013 15:13

    Random Transgenic Mouse

    We provide a service to generate transgenic mice by traditional pronuclear microinjection. Using this method, transgenes are inserted randomly into the genome.

    Expression of the transgene and the subsequent transgenic mouse phenotype may vary from line to line due to the nature of random gene insertion. We recommend to generate multiple independent trangenic mouse lines in order to interpret the experimental results.

    Available mouse strains: FVB, C57BL/6

    We also offer Knock-in and Knock-out Mice and Knock-in and Knock-out Rat services. For more information please contact us.

    Generation of transgenic mice by random insertion

    Step 1: Cloning of cDNA, promoter of interest, and other elements

    Step 2: Construction of the transgene vector

    Step 3: Pronuclear microinjection of vector DNA into mouse embryos

    Step 4: Transfer of injected embryo into recipient mothers

    Step 5: Genotyping of offspring to identify potential transgenic founders

    Step 6: Breeding to F1 or F2 progenies (optional)

    Published in Targatt services
    Monday, 11 March 2013 15:06

    Knock-in / Knock-out Mouse (7-months)

    We provide a high quality service for the generation of gene-targeted knock-in and knock-out mouse models. Our team has decades of experience in vector design, ES cell targeting and mouse handling. We will discuss your project needs with you and custom design your knockin/knockout mouse model. Our service includes consultation on available gene targeting vector design strategies and project assessment based on your model requirements.

    Service Milestones for the Generation of Knock-in/Knock-out Mouse Models

    • - Gene targeting vector construction and sequencing
    • - ES cell targeting, screening and expansion of positive ES cell clones
    • - Karyotyping of targeted ES cells
    • - Cre/FLP recombination (optional)
    • - Chimera production by blastocyst injection
    • - Breeding of chimeras for germline transmission
    • - Genotyping of offspring
    • - Transfer of heterozygous targeted mice to the customer
    • - Optional: breeding to generate homozygous mice

     

    Features

    Cost-effective

    • - Targatt has years of experience and an exceptionally high success rate in generating conventional gene-targeted mice with our proprietary mESC lines.

     

    High-Quality

    • - Our scientists have extensive experience in gene targeting and genetic mouse models. Our services always include a rigorous quality control with multiple check-points to ensure your projects are completed with highest accuracy. All mice are generated in and shipped from our California facility (NIH guidance certified).

    Please contact us with any questions regarding services not listed. We are happy to discuss your project with you and design customized strategies. We also offer Transgenic Mouse (Random Insertion) and Transgenic Rat Services (knockin, knockout).

    Testimony of Dr. Zhenheng Guo, PhD, Assistant Professor of Internal Medicine, Division of Endocrinology and Molecular Medicine, University of Kentucky

    Project: Germline-transmitted, conditional knock-out mice by tetraploid complementation

    "Overall, I am very satisfied with the quality of your service. After we received the mice, we did extensive studies to characterize them. All of the PCR reactions confirm the gene modifications are in the correct sites. We have also crossed mice with Cre mice to demonstrate that the Cre deleted the exon in heterozygous pups as expected. All data obtained showed that the mice were correctly targeted. In addition, I am very happy with the frequent communication with your scientists during the process. I highly recommend your services."

    Project types

    Express gene "X"

    Replace gene "X" with gene "Y"

    Delete gene "X"

    Random Integration

    Knockout/Knockin

    Knockout

    Knockin

     

    Conditional/inducible Knockout

    Conditional/inducible Knockin

       

    TARGATT

    (Site-Specific Knockin)

       

     

    Knock-in Mouse Models

    The introduction of a gene into a specified location of the mouse genome can be used for various applications. Mice can be homozygous or heterozygous for the inserted gene.

    • - Reporter genes (e.g. GFP, lacZ) are used for expression analysis of a gene of interest. The reporter gene is inserted into the gene of interested in-frame (non-disruptive), allowing for visualization of temporal and spatial gene expression pattern.
    • - Humanized disease models can be generated by inserting a human mutant gene or gene fragment into the corresponding mouse gene. The diseased human allel is thus transcribed in the appropriate genomic context and can be analyzed on behavioral, pathological, cellular and/or molecular level.
    • - DNA recombinases (CRE, FLP) can be inserted into a gene of interest. The celltype-specific expression of the recombinase then allows for gene inactivation in the desired tissue after crossing this knock-in mouse with a conditional knockout mouse.

     

    Knock-out Mouse Models

    The knockout technology is most commonly used for gene inactivation, either in a constitutive or conditional fashion.

    • - Constitutive knock-out mouse models are widely used to study gene function. The gene of interest is permanently inactivated in all cells of the animal. However, this non-conditional knock-out may cause lethality and is therefore not always recommended.
    • - Conditional knock-out models are inducible - the targeted gene is excised after crossing the mouse with a Cre-transgenic mouse line. Gene inactivation can be celltype-specific and/or chemically induced.

     

    Published in Targatt services
    Monday, 11 March 2013 15:01

    TARGATT Knock-down Mouse

    Gene knock-down using short hairpin RNA (shRNA) to inhibit expression of the corresponding gene has been widely used in gene function studies, drug discovery, and disease research.  Our TARGATT Technology allows us to generate in vivo shRNA knock-down mouse models in 3 months.

    In addition to our full service we also offer individual service options to generate your TARGATT shRNA knock-down mouse.

    You can prepare the DNA using the TARGATT Kit and we do the pronuclear microinjection for you. Or we can prepare the DNA that you then inject after setting up your own TARGATT mouse colony.

    Please contact us to discuss your project plan for your fast & site-specific TARGATT Knock-in Mouse or knock-down mouse services.

    Features of TARGATT shRNA Knock-down Mouse Services:

    • - shRNA copy number is controlled.
    • - Site-specific insertion into high expression locus guarantees the expression of shRNA.
    • - shRNA expression can be regulated by a tissue-specific promoter.
    • - Founder mice can be generated within 3 months.
    • - Full service including shRNA design, construction, and validation is available.

     

    targatt-antibodies-gentaur-knockin-knockout-mouse-1

    Applied Stem Cell Inc.’s proprietary TARGATT Technology enables highly efficient site-specific gene integration in mammalian cells and animals. This technology uses PhiC31 integrase to insert any gene of interest into a specific docking site that was pre-engineered into an intergenic and transcriptionally active genomic locus. Our TARGATT Technology improves several aspects in the generation of transgenic cell lines and animals:

    1. High integration efficiency mediated by  PhiC31 integrase reduces time and cost

    2. Site-specific integration at a pre-selected genomic locus eliminates position effect and ensures high expression levels of the transgene

    3. Integration at intergenic region ensures that no internal genes are interrupted

    4. Single copy gene integration eliminates repeat-induced gene silencing and genomic instability

    5. Site-specific integration allows a precise comparison of the effects of the transgenes among different lines.

    TARGATT Technology can be utilized for a variety of applications including reporter gene expression, gene knockdown and disease models.

    targatt-antibodies-gentaur-knockin-knockout-mouse-3

    Published in Targatt services
    Monday, 11 March 2013 14:50

    TARGATT Knock-in Mice (3-months)

    Targatt can create site-specific knock-in mice for you within 3 months. Using our novel TARGATT system, a gene of interest can be inserted at a well-characterized, transcriptionally-active locus in the mouse genome with guaranteed transgene expression. Tissue-specific and/or ubiquitous expression options are available. Please contact us for a list of plasmid construct with reporter genes. 

    In addition to our full service we also offer individual service options to generate your TARGATT knock-in mouse.

    You can prepare the DNA using the TARGATT Kit and we do the pronuclear microinjection for you. Or we can prepare the DNA that you then inject after setting up your own TARGATT mouse colony.

    Please contact us to discuss your project plan for your fast & site-specific knock-in or TARGATT Knock-down Mouse services.

    * Prices are a general guideline for academic institutes and may vary.  Please inquire for quote.

    Advantages of TARGATT Technology:

    Site-specific DNA integration (knock-in) in transcriptionally-active locus

    • - Ensures robust gene expression
    • - Eliminates unpredictable phenotypes caused by random integration
    • - Allows for proper comparison of different transgenes

    Single-copy integration

    • - Eliminates repeat-induced gene silencing and genomic instability.

     

    Insertion of intact transgene

    • - Avoids truncated transgenes with unexpected phenotype

    High integration efficiency

    • Save time and costs!

     

    targatt-antibodies-gentaur-knockin-knockout-mouse-1

     

    Applied Stem Cell Inc.’s proprietary TARGATT Technology enables highly efficient site-specific gene integration in mammalian cells and animals. This technology uses PhiC31 integrase to insert any gene of interest into a specific docking site that was pre-engineered into an intergenic and transcriptionally active genomic locus. Our TARGATT Technology improves several aspects in the generation of transgenic cell lines and animals:

    1. High integration efficiency mediated by  PhiC31 integrase reduces time and cost

    2. Site-specific integration at a pre-selected genomic locus eliminates position effect and ensures high expression levels of the transgene

    3. Integration at intergenic region ensures that no internal genes are interrupted

    4. Single copy gene integration eliminates repeat-induced gene silencing and genomic instability

    5. Site-specific integration allows a precise comparison of the effects of the transgenes among different lines.

    TARGATT Technology can be utilized for a variety of applications including reporter gene expression, gene knockdown and disease models.

    targatt-antibodies-gentaur-knockin-knockout-mouse-3

    Published in Targatt services

    cancer-antibodies-gentaur-1Un bebé de dos años que nació con el VIH ha sanado con terapia antirretroviral precoz

    Ayer, investigadores de amfAR, (Fundación para la investigación del sida en Estados Unidos) hicieron público en el marco de la 2013 Conference on Retroviruses and Opportunistic Infections, el primer caso documentado de curación de sida en un bebé nacido con VIH. Esta sanación, que fue posible con terapia precoz de antirretrovirales según los médicos, señala la necesidad de investigar más sobre el efecto de estos tratamientos en recién nacidos.

    Deborah Persaud, doctora de la Johns Hopkins University de Estados Unidos, describió ayer, tres de marzo de 2013, el primer caso documentado de un bebé curado del sida. Su anuncio fue realizado en la 2013 Conference on Retroviruses and Opportunistic Infections (CROI) de Atlanta (EEUU). 


    Persaud, investigadora de amfAR (The Foundation for AIDS Research) , detalló el caso de un bebé de dos años de edad de Mississippi diagnosticado con VIH al nacer, y que enseguida fue sometido a terapia antirretroviral. 

    A los 18 meses, el bebé dejó de tomar los antirretrovirales y su seguimiento médico se interrumpió. Cuando los médicos volvieron a verlo a los 23 meses, a pesar de que había dejado de su terapia durante cinco meses, constataron que el bebé tenía una carga viral indetectable. Una batería de pruebas altamente sensibles posteriores confirmó la ausencia del VIH. 

    La confirmación de la curación fue posible gracias a una donación que amfAR concedió a la doctora Persaud y a la doctora Katherine Luzuriaga, de la Universidad de Massachusetts, en septiembre de 2012. 

    La donación permitió que las médicos establecieran un colaboratorio de investigación para explorar y documentar posibles casos pediátricos de curación del VIH. En este colaboratorio participan además los doctores e investigadores Stephen Spector y Richman Doug, de la Universidad de California, San Diego; el Dr. Frank Maldarelli, del Instituto Nacional del Cáncer, y el Dr. Tae-Wook Chun, del Instituto Nacional de Alergias y Enfermedades Infecciosas.

     

    Diversas formas de tratamiento del VIH

    "El pediatra del bebé de Mississippi conocía nuestro trabajo y comunicó el caso a nuestro equipo, tan pronto como se enteró," explica Rowena Johnston, vicepresidenta de amfAR. "Gracias a que este colaboratorio ya estaba en marcha, los investigadores pudieron movilizarse inmediatamente y realizar las pruebas necesarias para determinar si realmente se trataba de un caso de curación del SIDA infantil”. 

    Según Persaud, pruebas exhaustivas han confirmado sin lugar a dudas que la madre y el bebé eran VIH positivo cuando este nació, y que en la actualidad no quedan signos de infección por VIH en el bebé, según los análisis realizados con los medios más sensibles disponibles. 

    El único caso documentado de cura del VIH hasta la fecha había sido el de Timothy Brown, el llamado "paciente de Berlín." En 2006, mientras era tratado por el VIH, al Sr. Brown le diagnosticaron leucemia. 

    Su médico trató entonces su leucemia con un trasplante de células madre de una persona nacida con una mutación genética que causa la inmunidad a la infección por VIH. Después del trasplante, el Sr. Brown pudo abandonar el tratamiento para el VIH sin recaídas. 

    Este nuevo caso apunta a la posibilidad de que diferentes poblaciones de personas con VIH podrían ser curadas de esta enfermedad de diferentes maneras. Mientras que el caso del señor Brown fue el resultado de una serie de complejos y costoso procedimientos de alto riesgo, este nuevo caso parece haber sido el resultado directo de una terapia antirretroviral relativamente barata. 

    "Teniendo en cuenta que esta sanación parece haberse logrado solo con terapia antirretroviral, es imperativo que aprendamos más acerca del sistema inmunológico de los recién nacidos y en qué se diferencia este del sistema inmunológico de los adultos; así como sobre los factores que han hecho posible que el bebé se haya curado”, explica Johnston. 

    El caso de Mississippi también pone de relieve la importancia de la identificación del VIH en mujeres embarazadas y de ampliar el acceso a tratamientos para prevenir la transmisión materno-infantil de la enfermedad. Asimismo, revela la necesidad de tratar de inmediato con antirretrovirales a los bebés que nacen seropositivos. 

    Acerca de amfAR

    amfAR, la Fundación para la Investigación del SIDA, es una de las principales organizaciones sin fines de lucro del mundo dedicada al apoyo de la investigación del SIDA, prevención del VIH, educación, tratamiento y su incidencia en las políticas públicas. Desde 1985, amfAR ha invertido más de 366 millones de dólares (unos 280 millones de euros) en sus programas y ha otorgado becas a más de 2.000 equipos de investigación de todo el mundo.

     

    Published in News
    Wednesday, 06 March 2013 15:50

    Targatt transgenic Kit

    TARGATT Transgenic Kit is designed to create site-specific, knock-in transgenic mice in a more efficient and significantly faster way over traditional methods. Generating transgenic mice by conventional methods (e.g. pronuclear microinjection or lentiviral injection) has several limitations, first of which is random insertion of the transgene. Random insertion of a transgene results in a position effect where either the transgene is prone to silencing or endogenous gene expression is disrupted. Furthermore, this position effect is compounded when a transgene is inserted as multiple copies, resulting in instability at the insertion locus.

    Using our proprietary site-specific DNA integration system, TARGATT Transgenic Kit, combined with our genetically TARGATT mouse embryos (cat.# AST-0001, AST-0002, AST-0003, AST-0004). Targatt offers high quality H11(Hipp11) and ROSA26 transgenic mouse kits with our TARGATT technology. Using our TARGATT Technology, you can generate your own knock-in mouse in just three months.

    targatt-antibodies-gentaur-knockin-knockout-mouse-1

    targatt-antibodies-gentaur-knockin-knockout-mouse-2

    If you prefer to generate a knock-in mouse model on your own, TARGATT Embryo H11(Hipp11) or Rosa26 and Transgenic Kits (2 or 5 microinjection size) are available for purchase.

    Background:

    TARGATT technology enables highly efficient site-specific gene integration in mammalian cells and animals1, 2. This technology uses øC31 integrase to insert any gene of interest into a docking site, pre-engineered in an intergenic region and transcriptionally active genomic locus. Our TARGATT technology improves several aspects in the generation of transgenic cell lines and animals: (1) High integration efficiency mediated by øC31 integrase reduces time and cost; (2) Site-specific integration at a pre-selected genomic locus eliminates position effect and ensures high level expression of the transgene; (3) Integration at intergenic region ensures that no internal genes are interrupted; (4) Single copy gene integration eliminates repeat-induced gene silencing and genomic instability; (5) Site-specific integration allows a precise comparison of the effects of the transgenes among different lines. TARGATT technology can be utilized for a variety of applications including reporter gene expression, gene knockdown, disease cell and animal models.

    targatt-antibodies-gentaur-knockin-knockout-mouse-3

    Click here to see all products

    Published in Promos
    Wednesday, 06 March 2013 15:35

    TARGATT embryos

    TARGATT embryos are derived from one of our genetically engineered mouse models. These mouse embryos can be used as embryo donors for creating site-specific transgenic mice in a more efficient and faster way compared to traditional methods. Generating transgenic mice by conventional methods (e.g. pronuclear microinjection or lentiviral injection) has several limitations, first of which is the random insertion of the transgene. Random insertion of a transgene results in a position effect where either the transgene is prone to silencing or endogenous gene expression is disrupted. Furthermore, this position effect is compounded when transgenes are inserted in multiple copies, resulting in genomic instability at the insertion locus. Using our proprietary site-specific DNA integration technology, TARGATT embryos combined with our TARGATT Transgenic Kit (cat# AST-1001 or AST-1002), you can generate your desired transgenic mouse models with guaranteed gene expression faster.

    Gentaur offers high quality H11 and ROSA26 TARGATT frozen embryos. Using our TARGATT Technology, you can generate your own knock-in mouse from H11 or ROSA26 embryos in 3 months. Our H11(Hipp11) and ROSA26 frozen embryos contain 3 straws with a total 45-60 cryopreserved embryos (8-cell stage/morula). They are shipped in a dry shipper containing liquid nitrogen. We also offer fresh H11 and ROSA26 embryos with each vial containing 25-35 fresh embryos (E3.5) in KSOM medium. We offer overnight shipping at ambient temperature. Embryos will be transferred to recipient(s) immediately upon arrival. US customers only.

    targatt-antibodies-gentaur-knockin-knockout-mouse-1

    targatt-antibodies-gentaur-knockin-knockout-mouse-2

    If you prefer to generate a knock-in mouse model on your own, TARGATT Embryo (H11 or Rosa26) and Transgenic Kits (2 or 5 microinjection size) are available for purchase.

    Background:

    TARGATT technology enables highly efficient site-specific gene integration in mammalian cells and animals1, 2. This technology uses øC31 integrase to insert any gene of interest into a docking site, pre-engineered in an intergenic region and transcriptionally active genomic locus. Our TARGATT technology improves several aspects in the generation of transgenic cell lines and animals: (1) High integration efficiency mediated by  øC31 integrase reduces time and cost; (2) Site-specific integration at a pre-selected genomic locus eliminates position effect and ensures high level expression of the transgene; (3) Integration at intergenic region ensures that no internal genes are interrupted; (4) Single copy gene integration eliminates repeat-induced gene silencing and genomic instability; (5) Site-specific integration allows a precise comparison of the effects of the transgenes among different lines. TARGATT technology can be utilized for a variety of applications including reporter gene expression, gene knockdown, disease cell and animal models.

    targatt-antibodies-gentaur-knockin-knockout-mouse-3

    Click here to see all products

    Published in Promos

    antibodies-gentaur-hivDr. Deborah Persaud of Johns Hopkins University today described the first documented case of a child being cured of HIV. The landmark findings were announced at the 2013 Conference on Retroviruses and Opportunistic Infections in Atlanta, GA.

    Dr. Persaud, an amfAR grantee, detailed the case of a two-year-old child in Mississippi diagnosed with HIV at birth and immediately put on antiretroviral therapy. At 18 months, the child ceased taking antiretrovirals and was lost to follow-up. When brought back into care at 23 months, despite being off treatment for five months, the child was found to have an undetectable viral load. A battery of subsequent highly sensitive tests confirmed the absence of HIV.

    Confirmation of the cure was made possible by a grant the Foundation awarded to Dr. Persaud and Dr. Katherine Luzuriaga of the University of Massachusetts in September 2012. The grant allowed Drs. Persaud and Luzuriaga to establish a research collaboratory to explore and document possible pediatric HIV cure cases. The collaboratory includes renowned researchers Drs. Stephen Spector and Doug Richman at the University of California, San Diego; Dr. Frank Maldarelli at the National Cancer Institute; and Dr. Tae-Wook Chun at the National Institute of Allergy and Infectious Diseases.

    "The child's pediatrician in Mississippi [Dr. Hannah Gay, a pediatric HIV specialist at the University of Mississippi] was aware of the work we were doing, and quickly notified our team as soon as this young patient's case came to her attention," said Dr. Rowena Johnston, amfAR vice president and director of research. "Because the collaboratory was already in place, the researchers were able to mobilize immediately and perform the tests necessary to determine if this was in fact a case of a child being cured."

    According to Dr. Persaud, comprehensive tests have confirmed beyond doubt that both mother and child were HIV positive when the child was born, and today no signs of HIV infection in the child can be detected by the most sensitive means available.

    The only other documented case of an HIV cure to date remains that of Timothy Brown, the so-called "Berlin patient." In 2006, while on treatment for HIV, Mr. Brown was diagnosed with leukemia. His physician was able to treat his leukemia with a stem-cell transplant from a person who was born with a genetic mutation causing immunity to HIV infection. Following the transplant, Mr. Brown was able to stop HIV treatment without experiencing a return of his HIV disease.

    This new case points to the tantalizing possibility that different populations of HIV-positive people might be cured in different ways. While Mr. Brown's case was the outcome of a complex, high-risk, and expensive series of procedures, this new case appears to have been the direct result of a comparatively inexpensive course of antiretroviral therapy.

    "Given that this cure appears to have been achieved by antiretroviral therapy alone," said Dr. Johnston, "it is also imperative that we learn more about a newborn's immune system, how it differs from an adult's, and what factors made it possible for the child to be cured."

    The Mississippi case also underscores the importance of identifying HIV-positive pregnant women, expanding access to treatment regimens than can prevent mother-to-child transmission, and of immediately putting infants on antiretroviral therapy in the event that they are born HIV positive.

    "We are proud to have played a leading role in bringing this first pediatric HIV cure to light," said amfAR CEO Kevin Robert Frost. "The case is a startling reminder that a cure for HIV could come in ways we never anticipated, and we hope this is the first of many children cured of HIV in the months and years to come." 

    Published in News
    Friday, 01 March 2013 13:45

    AccuPower DNA Ligation PreMix

    18AccuPowerDNALigationantibodies PreMix DualStar qPCR

    The AccuPower DNA Ligation PreMix is a lyophilized master mix containing T4 DNA Ligase, ATP, reaction buffer, and patented stabilizer. This DNA ligation premix is conveniently aliquoted in strip-tubes for reactions; you need only add DNAs to be ligated and water. The reaction will work for DNA ligation for all applications: blunt cloning, sticky end cloning and TA cloning. The premix is stable up to four months at room temperature and for three years at -20°C.

     

    Features and Benefits

    Ready to use premix: Minimal set up time and handling required
    Fast: Only 5 minutes for cohesive-end ligation and 10 minutes for blunt-end ligation at room temperature
    Stable: Enzyme activity for up to four months at room temperature and for three years in the freezer



    Application

    Cloning into vectors, library construction, TA cloning, linker ligation, and re-circlization of linear DNA

    19taq PyroHotStart HotStart

    Figure 1. Stability test of AccuPower DNA Ligation PreMix at room temperature.

     

    Lane 1 – 12: Lambda DNA / Hind lll fragment (1 µg)
    Lane 12 – 24: Lambda DNA / EcoR V fragment (1 µg)
    Lane 2, 3, 14, 15: Ligation with AccuPower Ligation PreMix stored at room temperature for 1 month
    Lane 5, 6, 17, 18: Ligation with AccuPower Ligation PreMix stored at room temperature for 2 months
    Lane 8, 9, 20, 21: Ligation with AccuPower Ligation PreMix stored at room temperature for 3 months
    Lane 11, 12, 23, 24: Ligation with AccuPower Ligation PreMix stored at room temperature for 4 months

    20pcr gentaur taq PyroHotStart HotStart

    Figure 2. DNA Ligation efficiency comparison between AccuPower DNA Ligation PreMix and other competitors’ products.

     

    Lane 1, 9: Intact Lambda DNA (1 µg)
    Lane 2 – 8: Lambda DNA / Hind lll fragment (1 µg)
    Lane 10 – 16: Lambda DNA / EcoR V fragment (1 µg)
    Lane 3, 4, 11, 12: Ligation with AccuPower Ligation PreMix
    Lane 5, 13: Ligation with T4 DNA Ligase from company N
    Lane 6, 14: Ligation with Quick Ligation Kit from company N
    Lane 7, 15: Ligation with LigFast Rapid DNA Ligation System from company P
    Lane 8, 16: Ligation with Ready-To-Go T4 DNA Ligase from company A

    Order Button1

    Published in Promos